Akebia Therapeutics Inc (AKBA)
1.37
+0.07
(+5.38%)
USD |
NASDAQ |
May 03, 16:00
1.42
+0.05
(+3.65%)
After-Hours: 20:00
Akebia Therapeutics Cash and Short Term Investments (Quarterly): 42.92M for Dec. 31, 2023
Cash and Short Term Investments (Quarterly) Chart
Historical Cash and Short Term Investments (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 42.92M |
| September 30, 2023 | 46.53M |
| June 30, 2023 | 53.57M |
| March 31, 2023 | 56.95M |
| December 31, 2022 | 90.47M |
| September 30, 2022 | 144.76M |
| June 30, 2022 | 143.89M |
| March 31, 2022 | 174.56M |
| December 31, 2021 | 149.80M |
| September 30, 2021 | 207.20M |
| June 30, 2021 | 246.99M |
| March 31, 2021 | 272.76M |
| December 31, 2020 | 268.69M |
| September 30, 2020 | 269.26M |
| June 30, 2020 | 295.35M |
| March 31, 2020 | 115.37M |
| December 31, 2019 | 147.69M |
| September 30, 2019 | 145.61M |
| June 30, 2019 | 136.76M |
| March 31, 2019 | 168.04M |
| December 31, 2018 | 321.64M |
| Date | Value |
|---|---|
| September 30, 2018 | 390.14M |
| June 30, 2018 | 402.12M |
| March 31, 2018 | 393.03M |
| December 31, 2017 | 317.79M |
| September 30, 2017 | 329.70M |
| June 30, 2017 | 321.22M |
| March 31, 2017 | 251.80M |
| December 31, 2016 | 260.34M |
| September 30, 2016 | 161.32M |
| June 30, 2016 | 188.65M |
| March 31, 2016 | 217.02M |
| December 31, 2015 | 138.45M |
| September 30, 2015 | 157.47M |
| June 30, 2015 | 152.79M |
| March 31, 2015 | 100.33M |
| December 31, 2014 | 108.92M |
| September 30, 2014 | 118.34M |
| June 30, 2014 | 124.25M |
| March 31, 2014 | 132.15M |
| December 31, 2013 | 32.56M |
Cash and Short Term Investments Definition
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
42.92M
Minimum
Dec 2023
295.35M
Maximum
Jun 2020
158.38M
Average
145.61M
Median
Sep 2019
Cash and Short Term Investments (Quarterly) Benchmarks
| Ocugen Inc | 39.46M |
| Aquestive Therapeutics Inc | 23.87M |
| SELLAS Life Sciences Group Inc | 2.53M |
| Protagonist Therapeutics Inc | 341.62M |
| Stoke Therapeutics Inc | 201.39M |